Poor
Not Aligned
Patient Risk:
High
Summary
Multiple claims about symptoms, incidence, location, timing, severity thresholds, and self-care are not supported by the provided FDA label excerpts. Several patient triage-style thresholds (e.g., specific fever value, difficulty swallowing/breathing, severe skin findings) are not explicitly present, creating potential misguidance.
Category Scores
Accurate Statements
In some cases, Cosentyx skin irritation can be a sign of a more serious underlying condition.
Partially supported. Label excerpts advise seeking immediate medical attention for serious hypersensitivity symptoms (5.2) and seek medical advice for eczema-like skin reactions (5.5), but do not explicitly state that skin irritation indicates a more serious underlying condition.
Unsupported Statements
Cosentyx (secukinumab) is a biologic medication used to treat plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.
No indication/approved uses section was provided in the available label excerpts.
Skin irritation (skin reactions) from Cosentyx can manifest as redness, itching, swelling, and burning sensations.
The excerpts only mention skin reactions resembling eczema and advice to seek medical advice for eczema-like signs/symptoms; they do not enumerate specific manifestations.
Skin reactions from Cosentyx can occur at the injection site or on other areas of the body.
No location details for skin reactions are present in the provided excerpts.
Cosentyx skin reactions are a common side effect, affecting up to 30% of patients.
No incidence rate or 'up to 30%' information is present in the provided excerpts.
The duration of Cosentyx skin irritation varies from person to person.
No duration/variability statements are included in the provided excerpts.
Skin reactions to Cosentyx typically resolve within 1–2 weeks after injection.
No time-to-resolution information is provided in the excerpts.
Some patients may experience prolonged skin irritation lasting up to several months.
No prolonged-duration information is provided in the excerpts.
Higher doses or more frequent injections of Cosentyx may be associated with longer-lasting skin irritation.
No dose-frequency relationship to skin-reaction duration is included in the provided excerpts.
Some patients may be more prone to skin irritation due to individual factors such as skin type or previous reactions to medications.
No general risk-factor statement (e.g., skin type, prior reactions to medications) is present in the provided excerpts.
Patients with pre-existing skin conditions such as eczema or acne may be more susceptible to skin irritation from Cosentyx.
Although eczema-like reactions are discussed, the excerpts do not state increased susceptibility in patients with pre-existing eczema or acne.
Applying cold compresses to the affected area can help reduce swelling and itching from Cosentyx skin irritation.
No home-care measures are mentioned in the provided excerpts.
Over-the-counter topical creams or ointments such as hydrocortisone can help soothe and calm the skin in response to Cosentyx skin irritation.
No OTC topical treatment recommendations are included in the provided excerpts.
In some cases, antihistamines may be prescribed to help alleviate itching and skin reactions from Cosentyx.
No antihistamine prescribing guidance is included in the provided excerpts.
Severe redness, swelling, or blistering after Cosentyx indicates the need for medical attention.
The excerpts advise seeking immediate medical attention for serious hypersensitivity reactions and medical advice for eczema-like signs/symptoms, but do not specifically define this exact severity-based skin triage criterion.
Difficulty breathing or swallowing after Cosentyx indicates the need for medical attention.
The excerpts advise immediate medical attention for serious hypersensitivity symptoms but do not explicitly list difficulty breathing or swallowing.
Fever over 100.4°F (38°C) after Cosentyx indicates the need for medical attention.
The excerpts advise contacting the doctor if symptoms of infection develop, but provide no numeric temperature threshold.
Contradictions
Important Omissions
The response does not address label-critical safety topics for Cosentyx that are present in the provided excerpts (e.g., counseling about infections/immune suppression, hypersensitivity risks and seeking immediate medical attention, and eczema-like reactions requiring medical advice are mentioned only partially and without broader infection/hypersensitivity context).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Unsupported quantitative and threshold-based triage claims (incidence up to 30%, specific fever cutoff, specific symptom triggers and severity criteria, and time-to-resolution) and unsupported self-care/OTC recommendations could mislead patients compared with the label excerpts, which provide different guidance (e.g., seek immediate attention for serious hypersensitivity symptoms; seek medical advice for eczema-like signs/symptoms; contact doctor if infection symptoms develop).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Many skin-reaction details (symptom lists, incidence %, location, duration, dose-frequency relationships, severity thresholds, numeric fever cutoff, and OTC/home-treatment guidance) are not supported by the provided FDA label excerpts.
Suggested Improvement
Limit claims to what the provided label excerpts support: advise that skin reactions resembling eczema may occur and instruct patients to seek medical advice if signs/symptoms of eczema develop; advise patients to seek immediate medical attention for serious hypersensitivity reactions; and instruct patients to contact their doctor if symptoms of infection develop. Remove unsupported numeric/temporal/threshold and OTC/home-treatment recommendations unless supported by additional label sections not provided here.